Lobe Sciences Ltd (CSE: LOBE )
0.0200 UNCHANGED Streaming Delayed Price Updated: 2:09 PM EDT, Sep 28, 2023 Add to My Watchlist
Press Releases about Lobe Sciences Ltd
Lobe Sciences Initiates Phase 1 Clinical Trial of L-130
June 27, 2023
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
January 26, 2023
EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END
Exposures Supply Chain
Lobe Sciences, Ltd. Enters Collaborative Clinical Research Agreement with Integrative Headache Medicine of New York to Study the Effects of L-130 in the Treatment of Chronic Cluster Headache
January 26, 2023
Dr. Lauren R. Natbony to be Principal investigator Vancouver, BC – January 26, 2023 — Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) (“Lobe” or the “Company”), a North American Biopharmaceutical company...
Exposures Product Safety
Lobe Sciences Ltd (LOBEF) increases its portfolio with several new chemical entities (NCEs)
January 19, 2023
Via AB Newswire
Lobe Sciences and Cantheon Capital Enter into Exclusive Investment Agreement to Fund $1.5M USD Toward Clinical Trials in Australia
September 01, 2022
Vancouver, British Columbia--(Newsfile Corp. - September 1, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"),...
Lobe Sciences Provides Corporate Update to Investors and Stakeholders
September 13, 2021
Vancouver, British Columbia--(Newsfile Corp. - September 13, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the...
Lobe Sciences Enters into Joint Venture with Virtual Psychedelics Incorporated to Develop Multi-Sensory Pods for Clinical Psychedelic Use
April 27, 2021
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or...